Processa Pharmaceuticals shareholders approve equity plan increase at 2026 annual meeting

Processa Pharmaceuticals, Inc. disclosed in an 8-K filed with the Securities and Exchange Commission that on July 30, 2026, the Company held its 2026 Annual Meeting of Shareholders.¹

At the meeting, shareholders approved an amendment to Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase the number of shares available for issuance under the plan by 200,000 shares.¹ The vote tally showed 579,877 shares for, 152,958 against, 2,700 abstaining, and 825,288 broker non-votes¹ on the incentive plan proposal.

Shareholders also voted on three other matters. All six director nominees, Justin Yorke, George Ng, Khoso Baluch, James Neal, Geraldine Pannu, and Dr. David Young, were elected to serve until the next Annual Meeting of Shareholders or until their successors have been duly elected and qualified.¹

The appointment of Cherry Bekaert, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified¹ with 1,541,664 shares in favor.

An advisory vote on executive compensation was also approved, with 640,726 shares for, 89,886 against, and 4,923 abstaining.¹

The filing noted that holders representing at least one-third of the voting power of the company's outstanding common stock were present in person or by proxy, constituting a quorum.¹ The record date for the meeting was June 1, 2026, per the filing. Details of the incentive plan amendment were previously described in the company's proxy statement, and a more detailed description of the plan was set forth in the Company's definitive Proxy Statement filed with the SEC on June 18, 2026, under Proposal No. 2, covering the amendment and restatement of the 2019 Omnibus Incentive Plan.¹ The 8-K was signed by Chief Financial Officer Russell Skibsted on August 4, 2026.